Clinical trial NCT02553135: Choroideremia Gene Therapy Clinical Trial
Official title: An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Choroideremia
Keywords: choroideremia, gene therapy
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2015-09-17
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients will be required to attend a total of 11 study visits over a 24 month period with an additional 3 year follow-up.

Detailed description: This is a Phase II, open label study involving patients with a clinical phenotype of choroideremia and a confirmed CHM genotype. Following consent, patients will be required to attend an initial screening visit (Visit 1). Within 2 weeks of the screening visit patients will undergo a surgical procedure (Visit 2) under general anesthesia which will include a standard vitrectomy, retinal detachment and administration of a subretinal injection of AAV2-REP1 (1x1011 genome particles). Patients will be required to attend a further 9 study visits (Visits 3-11) over a 24 month period for functional, and anatomical assessments as well as monitoring of adverse events. The primary endpoint is the change from baseline in visual acuity in the study eye, compared to control eye. Secondary study endpoints are, change from baseline in autofluorescence evaluation, microperimetry readings and other anatomic and functional outcomes (all in the study eye compared to control eye). Secondary endpoints also include safety assessments to be conducted throughout the study. The fellow eyes of these patients will be utilized as controls in this study and will receive no study treatment.

Eligibility criteria: Inclusion Criteria:

* 18 Years and older
* Male
* Able to give informed consent
* Genetically confirmed diagnosis of choroideremia
* Active disease visible clinically within the macula region
* Best-corrected visual acuity equal to or worse than 20/32 but better than or equal to 20/200 in the study eye.

Exclusion Criteria:

* Female
* Under the age of 18
* History of amblyopia in the study eye
* Men unwilling to use barrier contraception methods
* Relevant grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control
* Any other significant ocular and non-ocular disease/disorder or retinal surgery
* Contraindication to use of medications or contrast agents
* Participated in research study involving an investigational product in the past 12 weeks
* Having had gene or cellular therapy at any time prior to this study.

Primary outcomes:
measure: Change in Best Corrected Visual Acuity From Baseline
timeFrame: Baseline, 24 Months
Secondary outcomes:
measure: Change in Retinal Macular Autofluorescence From Baseline
timeFrame: 12 and 24 months
measure: Changes in Microperimetry From Baseline
timeFrame: Baseline to 24 months
measure: Number of Participants Who Experience an Adverse Event
timeFrame: 24 months
Other outcomes:
Locations:
city: Miami
country: United States
facility: Bascom Palmer Eye Institute, University of Miami
state: Florida
Study officials:
affiliation: UNIVERSITY OF MIAMI, BASCOM PALMER EYE INSTITUTE
name: BYRON LAM, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Davis JL. The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases. Am J Ophthalmol. 2018 Dec;196:xxv-xxix. doi: 10.1016/j.ajo.2018.08.038. Epub 2018 Sep 5.